RxDoctor Payments Data

Eric Pappert, MD

Neurology · San Antonio, TXNPI 1710968649

Payments from drug & device makers

$165,886in general payments, 2019–2025

Across 742 payments — averaging $223.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Neurotech Pharmaceuticals, Inc.$154K
  • Acadia Pharmaceuticals Inc$2K
  • Teva Pharmaceuticals USA, Inc.$1K
  • Neurocrine Biosciences, Inc.$1K
  • Abbott$949
  • AbbVie$823
  • plus $6K from 43 others

What the payments were for

  • Consulting fees$153,98993%
  • Speaking & faculty fees$1090%
  • Food & beverage$11,4237%
  • Education$3660%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$165,886 in reported general payments places this provider in the 85th percentile of 1,246 neurology providers in Texas.

See all neurology providers in Texas

Medicare billing

Part B allowed, 2024
$224,482
Medicare patients
395
Services billed
13,548

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
ApokynApomorphine Hcl25$685,521
GocovriAmantadine Hcl99$286,520
NuplazidPimavanserin Tartrate42$205,900
AustedoDeutetrabenazine14$161,071
RytaryCarbidopa/Levodopa106$147,915
InbrijaLevodopa15$76,830
Tetrabenazine12$44,003
NeuproRotigotine24$42,293
OngentysOpicapone27$28,007
BotoxOnabotulinumtoxina24$25,083
Entacapone119$23,129
Carbidopa-LevodopaCarbidopa/Levodopa726$21,975
Carbidopa-Levodopa ErCarbidopa/Levodopa184$11,911
Carbidopa33$10,976
MyoblocRimabotulinumtoxinb19$9,135

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
MDD US Operations, LLCGocovri$658$286,52099 claims
Acadia Pharmaceuticals IncNuplazid$1,751$205,90042 claims
Teva Pharmaceuticals USA, Inc.Austedo$1,208$161,07114 claims
Amneal Pharmaceuticals LLCRytary$82$147,915106 claims
Acorda Therapeutics, IncInbrija$487$76,83015 claims
UCB, Inc.Neupro$321$42,29324 claims
Neurocrine Biosciences, Inc.Ongentys$1,115$28,00727 claims
AbbVieBotox$823$25,08324 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,246 neurology providers in Texas.

Other neurology in San Antonio

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →